About Foamix

Foamix Pharmaceuticals is a specialty pharmaceutical company, developing innovative solutions for the field of dermatology.
The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo.
Having completed Phase II clinical trials of these product candidates, the company expects to initiate Phase III pivotal clinical trials for both in 2015.
Read More

Minocycline Foam

We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea. 
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2015


Read More

Recent News

Dec 16

Foamix Earns US$ 2.5 million Milestone Payment from Bayer HealthCare

May 12
Foamix to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference
Nov 14

Foamix Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014. Conference Call Scheduled for Monday November 17, 2014 at 8:30am Eastern / 5:30am Pacific